Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01798992 · ClinicalTrials.gov registry record · Phase 4
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT01798992 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 56 participants.
The verdict
NCT01798992, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
The primary goal of the study is to measure in the intact human heart, the alterations in gene expression over time that are associated with reverse remodeling in response to β-blockade. The second goal is to investigate the signaling mechanisms which in turn are responsible for these changes in gene expression, and the third goal is to determine the relationship between intrinsic systolic dysfunction and remodeling of the left ventricle. This will be accomplished by measuring ventricular size, function, and gene expression in myocardial tissue samples obtained by percutaneous biopsy prior to initiation of β-blockade and at 3 and 12 months after start of therapy. The specific Aims and Hypotheses to be tested are: 1. Aim: Determine the changes in gene expression associated with changes in intrinsic systolic function and with functional decompensation in the intact, failing human heart. a. Hypothesis: Changes in the expression of select genes precede or accompany changes in left ventricular systolic function in humans with idiopathic dilated cardiomyopathy (IDC). 2. Aim: Identify signaling mechanisms responsible for alterations in expression of key genes involved in mediation of ventricular hypertrophy or contractile dysfunction. a. Hypothesis: Myocardial-failure-associated regulation of select messenger ribonucleic acids and proteins are related to left ventricular wall stress and neurohormonal signaling. 3. Aim: In the relationship between contractile dysfunction and dilatation/remodeling, determine the relationship between contractile dysfunction and structural remodeling. b. Hypothesis: the contractile dysfunction is primary and structural remodeling secondary.
Interventions
- DRUG Carvedilol
- DRUG Metoprolol succinate
- DRUG Metoprolol succinate + doxazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2000-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01798992
The ClinicalTrials.gov registry entry for NCT01798992 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carvedilol is the first listed.
NCT01798992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01798992 about?
NCT01798992 is a clinical study titled "Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart". The primary goal of the study is to measure in the intact human heart, the alterations in gene expression over time that are associated with reverse remodeling in response to β-blockade. The second goal is to investigate the signaling mechanisms which in turn are responsible for these changes in gen...
What is the current status of trial NCT01798992?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2000-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT01798992?
The interventions under investigation include: Carvedilol (DRUG), Metoprolol succinate (DRUG), Metoprolol succinate + doxazosin (DRUG).
Who is sponsoring clinical trial NCT01798992?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.